CD8A and neoplasm: Specifically, anti-PD-L1 therapy could amplify tumor antigen-specific CD8+ T cells in young mice, but not in aged mice (Fig. 2F), and the ability to secrete killer cytokines IFN-γ and TNF-ɑ of T cells is also significantly improved in young mice (Fig. 2G–I).